Mylan Inc. June 26 announced that its subsidiary, Mylan Pharmaceuticals Inc., has launched a generic version of Janssen Pharmaceutical Inc.'s Micronor (norethindrone) 0.35 mg tablets (28-day cycle).
Micronor is indicated to prevent pregnancy.
Mylan said its partner, Famy Care Ltd., received final approval from the Food and Drug Administration for this generic product.
Norethindrone 0.35 mg tablets had U.S. sales of approximately $57.2 million for the 12 months ended March 31, according to IMS Health.
Mylan is based in Pittsburgh.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.